| Literature DB >> 27935690 |
Alexandra S Whale1, Alison S Devonshire1, George Karlin-Neumann2, Jack Regan2, Leanne Javier2, Simon Cowen3, Ana Fernandez-Gonzalez1, Gerwyn M Jones1, Nicholas Redshaw1, Julia Beck4, Andreas W Berger5, Valérie Combaret6, Nina Dahl Kjersgaard7, Lisa Davis8, Frederic Fina9, Tim Forshew10, Rikke Fredslund Andersen11, Silvia Galbiati12, Álvaro González Hernández13, Charles A Haynes14, Filip Janku15, Roger Lacave16, Justin Lee17, Vilas Mistry18, Alexandra Pender19, Anne Pradines20, Charlotte Proudhon21, Lao H Saal22, Elliot Stieglitz23, Bryan Ulrich24, Carole A Foy1, Helen Parkes1, Svilen Tzonev2, Jim F Huggett1,25.
Abstract
This study tested the claim that digital PCR (dPCR) can offer highly reproducible quantitative measurements in disparate laboratories. Twenty-one laboratories measured four blinded samples containing different quantities of a KRAS fragment encoding G12D, an important genetic marker for guiding therapy of certain cancers. This marker is challenging to quantify reproducibly using quantitative PCR (qPCR) or next generation sequencing (NGS) due to the presence of competing wild type sequences and the need for calibration. Using dPCR, 18 laboratories were able to quantify the G12D marker within 12% of each other in all samples. Three laboratories appeared to measure consistently outlying results; however, proper application of a follow-up analysis recommendation rectified their data. Our findings show that dPCR has demonstrable reproducibility across a large number of laboratories without calibration. This could enable the reproducible application of molecular stratification to guide therapy and, potentially, for molecular diagnostics.Entities:
Mesh:
Substances:
Year: 2017 PMID: 27935690 DOI: 10.1021/acs.analchem.6b03980
Source DB: PubMed Journal: Anal Chem ISSN: 0003-2700 Impact factor: 6.986